Echo IQ (EIQ) Investor update summary

Business and financial position

• Raised AUD 110 million, strengthening the balance sheet and enabling commercial expansion and R&D acceleration.

• Operating cash burn remains stable at AUD 2.5–2.7 million per quarter, with pro forma cash at AUD 107.6 million post-raise.

• Strong capital position supports scaling, product development, and FDA launch preparations.

Commercial progress and pipeline

• Over 70 customers in various contract phases, representing about 300 hospitals, with rapid deal closure expected.

• Fivefold increase in pricing proposals and contracts in review, driven by new EchoSolv VIEW and SHADOW programs.

• Streamlined implementation and multithreaded sales approach accelerating book-to-bill and revenue recognition.

• Enterprise deals could provide access to over 300 hospitals, with adoption spreading from single centers to networks.

Strategic partnerships and data assets

• Strategic partnership with Pro Medicus includes AUD 10 million upfront and future revenue sharing, with integration into Visage 7 PACS.

• Acquisition of Advara HeartCare data, one of the largest global databases, enhances competitive moat and AI capabilities.

• Collaboration with Mayo Clinic includes both clinical validation (VALIDATE) and a three-year commercial agreement, with potential for extension.